Scarica l'app Stockscreener
1.90
0.00%
0.00
Dopo l'orario di chiusura:
1.94
0.04
+2.11%
Precedente Chiudi:
$1.90
Aprire:
$1.9
Volume 24 ore:
115.43K
Relative Volume:
0.47
Capitalizzazione di mercato:
$51.10M
Reddito:
-
Utile/perdita netta:
$-13.76M
Rapporto P/E:
-2.043
EPS:
-0.93
Flusso di cassa netto:
-
1 W Prestazione:
-13.64%
1M Prestazione:
+12.43%
6M Prestazione:
+65.22%
1 anno Prestazione:
+53.23%
Intervallo 1D:
$1.8408
$1.96
Intervallo di 1 settimana:
$1.7657
$2.19
Portata 52W:
$0.512
$2.60
Neurosense Therapeutics Ltd Stock (NRSN) Company Profile
Nome
Neurosense Therapeutics Ltd
Settore
Industria
Telefono
-
Indirizzo
-
Confronta NRSN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NRSN
Neurosense Therapeutics Ltd
|
1.90 | 51.10M | 0 | -13.76M | 0 | -0.93 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.03 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.74 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
329.77 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
545.11 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
244.32 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Neurosense Therapeutics Ltd Borsa (NRSN) Ultime notizie
NeuroSense Therapeutics (NRSN) Expected to Announce Earnings on Tuesday - Defense World
Why It Makes Sense To Keep An Eye On NeuroSense Therapeutics - RTTNews
Jane Street Group LLC Makes New Investment in NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) - Defense World
Top Nasdaq Companies by Market Cap Ranked by Kalkine - Kalkine Media
NeuroSense Therapeutics (NASDAQ:NRSN) Trading Up 1.2% – Here’s What Happened - Defense World
Citadel Advisors LLC Buys 219,717 Shares of NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) - Defense World
NRSNNeuroSense Regains Compliance with Nasdaq's Minimum Equity Requirement - mx.advfn.com
NRSN stock touches 52-week high at $1.65 amid robust gains - Investing.com
NRSN stock touches 52-week high at $1.52 amid growth optimism - Investing.com Australia
D. Boral Capital Begins Coverage on NeuroSense Therapeutics (NASDAQ:NRSN) - Defense World
D. Boral Capital Initiates Coverage of NeuroSense Therapeutics (NRSN) with Buy Recommendation - Nasdaq
Why This Nano-Cap Stock Might Skyrocket To $14, Per Analyst InsightsNeuroSense Therapeutics (NASDAQ:NRSN) - Benzinga
Boral Capital starts NeuroSense stock with Buy, $14 target By Investing.com - Investing.com South Africa
This NeuroSense Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Monday - Benzinga
NeuroSense (NRSN) Receives Buy Rating with Promising Outlook | N - GuruFocus
Boral Capital starts NeuroSense stock with Buy, $14 target - Investing.com
Amyotrophic Lateral Sclerosis Market Set for Groundbreaking - openPR.com
NeuroSense Completes PrimeC Manufacturing Scale-Up for Canadian Launch - TipRanks
NeuroSense Therapeutics Announces Successful Completion of Commercial Manufacturing Scale-Up for PrimeC in Preparation for Potential Canadian Market Launch - Nasdaq
NeuroSense Regains Compliance with Nasdaq's Minimum Equity Requirement - ADVFN
NeuroSense Therapeutics to Participate in the 2024 International Symposium on ALS/MND - ADVFN
NeuroSense Therapeutics (NASDAQ:NRSN) Stock Price Down 0.9% – Here’s Why - Defense World
NeuroSense Therapeutics Advances ALS Treatment and Strategic Partnership - TipRanks
NeuroSense Therapeutics Releases Letter to Shareholders Outlining Clinical Progress, Regulatory Strategy, and Partnership Update - Quantisnow
Head-To-Head Contrast: NeuroSense Therapeutics (NASDAQ:NRSN) versus TFF Pharmaceuticals (NASDAQ:TFFP) - Defense World
NLS and Kadimastem: Swiss-israeli merger in ALS - European Biotechnology Magazine
Neurosense Therapeutics Announces Phase 2B Microrna Data - marketscreener.com
Groundbreaking ALS Treatment Cuts Disease Progression by 33%, Boosts Survival 58% - Stock Titan
NeuroSense Therapeutics Announces Transformative Phase 2b MicroRNA Data, Highlighting PrimeC's Promise as a Disease-Modifying ALS Treatment - PR Newswire
NeuroSense Therapeutics Reports 2024 Financial Results - TipRanks
NeuroSense Therapeutics Reports 2024 Financial Results and Advances ALS Treatment - MSN
NeuroSense Therapeutics Reports Year End 2024 Financial Results and Provides Business Updates - The Malaysian Reserve
NeuroSense’s ALS drug PrimeC shows success in phase 2b, eyes final trial - MSN
Breakthrough ALS Treatment Shows Disease-Modifying Results in Phase 2b Trial - Stock Titan
NeuroSense Therapeutics to Present New Data from PrimeC's Phase 2b Trial in ALS at the Annual American Academy of Neurology Meeting - PR Newswire
Lou Gehrig's Disease Pipeline: 75+ Innovators Pioneering Breakthrough Therapies | DelveInsight - openPR.com
NeuroSense Updates on Pharmaceutical Partnership Discussions - TipRanks
Amyotrophic Lateral Sclerosis Pipeline: Advancing the Future with 50+ Innovators Leading Breakthrough Therapies - openPR.com
Market Alert: Hinge Health's Multi-Billion Dollar Expected IPO Highlights 600% Valuation Opportunity for DarioHealth - Business Wire
Motor Neuron Disease Clinical Pipeline | 180+ Companies Advancing Next-Generation Therapies - openPR.com
NeuroSense Therapeutics (NRSN) to Release Earnings on Monday - Defense World
NeuroSense Therapeutics: A Promising Biotech Stock in the Neurodegenerative Space - eng.expertclub.ge
Market Alert: NeuroSense Therapeutics Advances Toward Early Canadian Commercialization of ALS Drug - Business Wire
NeuroSense Advances PrimeC Commercialization in Canada - TipRanks
Neurosense Therapeutics Ltd Azioni (NRSN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.45%
0.86%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):